InVivo Therapeutics Corporation Names Dr. Christopher D. Pritchard Chief Science Officer

InVivo Therapeutics Corporation Names Dr. Christopher D. Pritchard Chief Science Officer


CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 13, 2010 - InVivo Therapeutics Corporation announced today that Dr. Christopher Pritchard will assume the role of Chief Science Officer, effective immediately. Dr. Pritchard has served several important research and development roles since he began his work with InVivo co-founder Frank Reynolds in 2007. His most recent position at InVivo was Director of Research & Development.

"After years of working side by side with InVivo's globally renowned scientific advisory board, I consider it a true honor to assume the Chief Science Officer position. I look forward to the challenges and rewards of the position and remain focused on executing InVivo's scientific strategic plans.

"InVivo has developed true platform technologies around biomaterials. Our pipeline includes technologies to treat a range of spinal cord injuries (SCI) and central nervous disease processes. Our biomaterials are effective, but we have achieved enhanced effectiveness in non-human primate studies when the biomaterials are used with combinations of drugs and human neural stem cells. With a strong IP portfolio and a celebrated team, InVivo is an exciting emerging company in the central nervous system space. As our CEO Frank Reynolds says, we are creating a new clinical franchise in medicine, and if our primate results transfer to humans, we'll change the face of neuroscience forever. Although we hope to provide a range of treatment options for multiple central nervous system conditions, our immediate focus is helping our friends with traumatic spinal cord injuries."

According to InVivo Therapeutics CEO Frank Reynolds, "Christopher is a rare breed of scientist in his understanding of both the scientific and business sides of our organization. When I met Chris he was seeking information for a loved one's spinal cord injury, and when I mentioned we were hiring for our SCI team Chris was pumped. I believe Chris was drawn to my passion but I was drawn to the sparkle in his eye when we discussed InVivo's mission."

Since that time Dr. Pritchard has left his imprint on InVivo. He has been named a "Whiz Kid of Boston," become a member of the Union League of Philadelphia, and has led InVivo's non-human primate studies. A tireless worker with an intellect to match, Dr. Pritchard completed his PhD at MIT in less than 29 months while publishing 8 peer reviewed journal articles in areas critical to InVivo's success.

InVivo Therapeutics Corporation is a Cambridge, MA medical device company focused on combining polymers and stem cells to restore function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of research initiated in the laboratories of Robert Langer, PhD, of the Massachusetts Institute of Technology, Jay Vacanti, MD, of the Massachusetts General and Children's Hospitals in Boston, and Yang Teng, PhD, MD, of Harvard's Brigham and Women's Hospital.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6426313&lang=en

 

 

 

Contact: InVivo Therapeutics Corporation
Frank Reynolds 617-475-1517
[email protected]

 

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.